Hemoglobin News and Research RSS Feed - Hemoglobin News and Research

Study finds no evidence that testosterone replacement therapy increases cardiovascular risk

Study finds no evidence that testosterone replacement therapy increases cardiovascular risk

Fears of a link between testosterone replacement therapy and cardiovascular risk are misplaced, according to a review published in this month's Mayo Clinic Proceedings. The therapy has come under widespread scrutiny in recent months, including by a federal Food and Drug Administration panel convened last fall. [More]
FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine. [More]

Novel device may speed up medical decision-making for critically injured trauma patients

A tool that surgeons use for monitoring a patient's blood level in physicians' offices may also save valuable minutes in medical decision-making for critically injured trauma patients, according to study results published in the January 2015 issue of the Journal of the American College of Surgeons. [More]
CytoSorbents starts trading on The Nasdaq Capital Market

CytoSorbents starts trading on The Nasdaq Capital Market

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO". [More]
Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Cervical cancer is, in many ways, a shining example of how successful the war on cancer can be. Thanks largely to the advent of Pap smear screening, U.S. cervical cancer deaths decreased dramatically, by more than 60 percent, between 1955 and 1992. In the last two decades, better treatment outcomes and more powerful imaging techniques have steadily pushed 5-year survival rates ever higher. [More]
Deoxygenated hemoglobin triggers conversion of nitrite to nitric oxide

Deoxygenated hemoglobin triggers conversion of nitrite to nitric oxide

Understanding how nitrite can improve conditions such as hypertension, heart attack and stroke has been the object of worldwide research studies. New research from Wake Forest University has potentially moved the science one step closer to this goal. [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Raising awareness of sickle cell disease risks

Raising awareness of sickle cell disease risks

Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier, according to research published in the International Journal of Medical Engineering and Informatics. [More]
Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. [More]
Hydroxyurea therapy offers safe, effective disease management of SCA

Hydroxyurea therapy offers safe, effective disease management of SCA

Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute of a key clinical trial studying the drug's efficacy. [More]

Point of care hemoglobin analyzer launched by EKF Diagnostics at Medica 2014

EKF Diagnostics, the global diagnostics company, has introduced the DiaSpect TM point of care (POC) hemoglobin analyzer at Medica 2014, 12-15th November, Düsseldorf, Germany. Alongside this new product, EKF exhibited a new version of its Hemo Control hemoglobin analyzer, the industry-leading Biosen glucose and lactate analyzer, as well as previewing SensPoint, a new lactate analyzer designed for use in professional medical settings. [More]
EKF Molecular Diagnostics to present at AMP annual meeting

EKF Molecular Diagnostics to present at AMP annual meeting

EKF Diagnostics, the global diagnostics company, has announced that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology (AMP) annual meeting on booth 1028, to discuss with delegates the predicted outcomes of its research collaboration with Massachusetts General Hospital (MGH). [More]
New handheld probe can produce detailed images of blood vessels, other internal body parts

New handheld probe can produce detailed images of blood vessels, other internal body parts

A new handheld probe developed by a team of university and industry researchers in the Netherlands and France could give doctors powerful new imaging capabilities right in the palms of their hands. The imaging system, which is described in a paper published in The Optical Society's open-access journal Optics Express, shrinks a technology that once filled a whole lab bench down to a computer screen and a small probe about the size of a stapler. [More]
HemoCue WBC Analyzers now used in US hospitals for handling suspected Ebola patients

HemoCue WBC Analyzers now used in US hospitals for handling suspected Ebola patients

HemoCue America, a leader in advanced point-of-care testing (POCT) systems, today announced delivery of HemoCue White Blood Cell (WBC) Analyzers to a number of US hospitals. The WBC Analyzers are a part of emergency preparedness plans for handling of suspected Ebola patients. [More]
Seno Imagio breast imaging system and associated predictive model can help eliminate breast biopsies

Seno Imagio breast imaging system and associated predictive model can help eliminate breast biopsies

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced that the use of the Seno Imagio breast imaging system and the associated predictive model appear to have the potential to significantly improve the physicians’ ability to accurately rule out breast cancer compared to traditional ultrasound alone. [More]
DOST imaging may help predict tumor response before starting treatment

DOST imaging may help predict tumor response before starting treatment

A Dartmouth study suggests that it may be possible to use Diffuse Optical Spectroscopic Tomographic imaging (DOST) to predict which patients will best respond to chemotherapy used to shrink breast cancer tumors before surgery. These findings could eliminate delays in effective early treatment for tumors unlikely to respond to neoadjuvant chemotherapy (NAC). [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Viewpoints: Health law opposition not propelling GOP; keep politics out of the fight against Ebola

Viewpoints: Health law opposition not propelling GOP; keep politics out of the fight against Ebola

As recently as April, Obamacare was going to be the silver bullet for Republicans in this year's midterm elections. The leader of conservative advocacy group Americans for Prosperity said his plan was to make Obamacare "the No. 1 issue in the country." Senate Minority Leader Mitch McConnell, R-Ky., declared that the law would be "a huge disaster in 2014" and the deciding factor in November. Well, that was then. Now, three weeks from Election Day, some GOP challengers trying to knock off Democratic incumbent senators have scaled back their anti-Obamacare ads in favor of new targets such as the economy and national security (10/13). [More]

CSL Plasma chooses OrSense's NBM200 Hb testing device for screening Hb levels in plasma donors

OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announced that CSL Plasma, Germany, has completed the transition to OrSense's NBM200 Hb testing device for screening of Hb levels in plasma donors. [More]